171 results about "Antigen binding site" patented technology

The invention provides for a polyvalent protein complex (PPC) comprising two polypeptide chains generally arranged laterally to one another. Each polypeptide chain typically comprises 3 or 4 “v-regions”, which comprise amino acid sequences capable of forming an antigen binding site when matched with a corresponding v-region on the opposite polypeptide chain. Up to about 6 “v-regions” can be used on each polypeptide chain. The v-regions of each polypeptide chain are connected linearly to one another and may be connected by interspersed linking regions. When arranged in the form of the PPC, the v-regions on each polypeptide chain form individual antigen binding sites.

Masking ligands for reversibly concealing the antigen-binding site of an antibody comprise epitopes of the antibody and a cleavable linker. Methods for making masking ligands comprise joining at least two copies of the epitope of an antibody to a cleavable polypeptide linker.

A recombinant or synthetic antibody or fragment thereof, said antibody or fragment thereof including three complementarity determining regions (CDR1_L or H, CDR2_L or H and CDR3_{L or H}) for forming an antigen binding site that is capable of binding to a non functional P2X7 receptor but not capable of binding to a functional P2X7 receptor.

The present invention relates to binding molecules, such as amino acid sequences with multiple antigen binding sites. In particular, the binding molecules of the present invention have at least two antigen binding sites that partially or fully overlap with each other and that are directed against at least two different naturally occurring binding molecules. The invention further relates to uses of such binders, for example in methods for inhibiting and/or blocking of the interaction between said at least two naturally occurring binding molecules and a third naturally occurring binding molecule.

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

The invention discloses immunoglobulin fusion proteins designed to bind both CD47 and a tumor cell antigen. The immunoglobulin fusion proteins include a SIRP afla moiety that binds CD47 and an antigen binding site for a tumor cell antigen.

Endothelialization of vascular surfaces. According to one aspect, the invention involves a technique for re-endothelializing an artery whose endothelial layer has been damaged by balloon angioplasty. The technique comprises, in one embodiment, introducing into the bloodstream of a patient, prior to performing the angioplasty, a quantity of a bispecific antibody, the bispecific antibody having a first antigen binding site directed against a surface marker common to both endothelial progenitor cells (EPCs) and endothelial cells (ECs) and having a second antigen binding site directed against a subendothelial epitope. The bispecific antibody is introduced in a quantity sufficient to bind a substantial percentage of circulating EPCs and circulating ECs. In this manner, once the angioplasty has been performed and the target epitopes on the subendothelium have been exposed, the bispecific antibodies that have already become bound to the circulating EPCs and ECs also then bind to the subendothelium. Thus seeded by the bound EPCs and ECs, the exposed subendothelium is covered after a short period of proliferation and differentiation.

A protein complex comprising (i) a first fusion protein comprising (a) a first polypeptide that comprises a first antigen-binding site and (b) a first binding protein linked to a terminus of the first polypeptide; and (ii) a second fusion protein comprising (a) a second polypeptide that comprises a second antigen-binding site and (b) a second binding protein linked to a terminus of the second polypeptide, wherein the protein complex comprises an amino acid sequence that enables cleavage between the first polypeptide and the first binding protein, and/or between the second polypeptide and the second binding protein, as well as a method for preparing a bi-specific antibody and related methods and compositions.

A bispecific antigen binding protein complex comprising a first polypeptide comprising a first antigen binding site at an N terminus; a second polypeptide comprising a second antigen binding site at an N terminus; and a linker connecting the first polypeptide and the second polypeptide; wherein the linker comprises a tag at one terminus thereof, and wherein the tag is connected to a C-terminus of the first polypeptide or to an N-terminus of the second polypeptide, and comprises a cleavable amino acid sequence; as well as related compositions and methods.

The invention provides a quick test dipstick used for testing a specific antigen of Brucella, which comprises a reaction membrane and a binder release liner. The reaction membrane is provided with a testing strap coated with a bp26 monoclonal antibody or bp26 polyclonal antibody and a quality control strap coated with anti-IgG; the binder release liner is coated with the bp26 monoclonal antibody which is marked by colloidal gold to be different from an antigen binding site on the reaction membrane. A membrane chromatography double antibody sandwich method is applied for detecting the specific antigen of the Brucella in a specimen. As the dipstick is adopted for test, the operation is simple, convenient, quick and concise, requiring no special equipment and facilities as well as professional training. Furthermore, the dipstick has clear and easy-identity results, simple operation and easy popularization, is applicable to matrixes, field tests of emergency on a large scale and the study of epidemiology and can aid in the infection diagnostics of the Brucella.

The invention relates to an antigen binding site for binding to a P2X₇ receptor, the antigen binding site being de-fined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

The invention discloses a method for preparing a porcine hepatitis E virus (HEV) total antibody enzyme-linked immuno sorbent assay (ELISA) detection kit. The method for preparing the porcine HEV total antibody ELISA detection kit comprises the following steps: preparing an HEV coating antigen; preparing an HEV labeled antigen; preparing an HEV labeled antigen-HRP marker; and diluting an S antigen according to a certain ratio by adopting a carbonate buffer solution, adding the diluent into an ELISA plate with the volume of 100mu l for each pore, packaging the ELISA plate in an aluminum coating bag filled with a drying agent, and finishing the coating. An ELISA detection method for rapidly and efficiently detecting porcine HEV total antibodies is established, the coating antigen and antibodies in serum are specifically bonded according to a dual antigen sandwich method principle, an antigen-antibody complex and the labeled antigen are bonded to carry out antigen-antibody reaction, the two antigens are bonded with different antigen-binding sites, the method is high in sensitivity, high in specificity and high in repeatability, a corresponding technical guarantee is provided for HEV epidemiology large-scale surveys, and a theoretical basis is provided for well preventing and controlling porcine HEV epidemic diseases.